Recent Trends in Research with Human Pluripotent Stem Cells: Impact of Research and Use of Cell Lines in Experimental Research and Clinical Trials
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The human pluripotent stem cell (hPSC) research landscape is rapidly evolving. To assess possible novel trends in hPSC usage, we analyzed experimental hPSC research published from 2014 to 2016 and compared our data with those of earlier periods. The number of papers describing experimental work involving hPSCs increased further with clear differences in the scientific impact of publications from different countries. Our results confirm the leading position of US-based hPSC research, although to a lesser degree than observed previously. Our data reveal that research into human induced pluripotent stem cells alone surpassed human embryonic stem cell (hESC) research by 2015 and rapidly grew after that. We also report on continuing and even slightly growing research activities in the hESC field as well as on a generally declining rate of the generation of new hESC lines. An increasing portion of new hESC lines represents disease-specific and clinical-grade cell lines. The previously noted usage of only a few early established hESC lines in the vast majority of scientific work is sustained. We also provide a comprehensive overview on clinical trials on the basis of hPSCs. We find that the vast majority of those trials are based on hESC-derived cell products that were generated from an only limited number of relatively old cell lines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RIKEN suspends first clinical trial involving induced pluripotent stem cells
Garber, K. (2015) · Nature Biotechnology · doi:10.1038/nbt0915-890 · Cited by 215 · cited 1×
“However, the only study using autologous hiPSC lines was put on hold because of mutations of unknown potential risk in the hiPSC source material (Garber, 2015).”
BackgroundA Standard Nomenclature for Referencing and Authentication of Pluripotent Stem Cells
Kurtz, A., Seltmann, S., Bairoch, A., Bittner, M.-S., Bruce, K., Capes-Davis, A., Clarke, L., Crook, J. M., Daheron, L., Dewender, J., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.12.002 · Cited by 47 · cited 1×
“A recently proposed standard nomenclature for hPSC lines would be required to trace the cells and their data (Kurtz et al., 2018).”
BackgroundSelf-citationMaking it personal: The prospects for autologous pluripotent stem cell-derived therapies
Blair, N. F., & Barker, R. A. (2016) · Regenerative Medicine · doi:10.2217/rme-2016-0057 · Cited by 22 · cited 1×
“Whether autologous, personalized hiPSCs, or HLA-haplobanks of hiPSC lines, will become an affordable option for personalized medicine remains disputable (Blair and Barker, 2016).”
Background
Cited by
Volpato, V., & Webber, C. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.042317 · Cited by 379
“High variability in differentiation potential and genetic stability between iPSC lines remain subjects of intense research (Guhr et al., 2018).”
Personalized Hydrogels for Engineering Diverse Fully Autologous Tissue Implants
Edri, R., Gal, I., Noor, N., Harel, T., Fleischer, S., Adadi, N., Green, O., Shabat, D., Heller, L., Shapira, A., et al. (2019) · Advanced Materials · doi:10.1002/adma.201803895 · Cited by 128
Metadata
- Authors
- Guhr, A., Kobold, S., Seltmann, S., Seiler Wulczyn, A. E. M., Kurtz, A., & Löser, P.
- Venue
- Stem Cell Reports
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 11
- Issue
- 2
- Pages
- 485-496
- ISSN
- 2213-6711 (ISSN-L)
- OpenAlex
- W2884305074
- Cited by
- 58
- References
- 3
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.